[Special Stock] Pharma Research Advances 200 Billion Capital Increase Payment Date by Two Months, Hits Record High

Two Months Ago, European PEF Investment Attraction
Liquidity Secured by Change in Paid-in Capital Subscription Date
Growth Expectations in Beauty and Medical Device Markets

Pharmaresearch has recorded an all-time high. It appears to have been influenced by the news that the payment date for the 200 billion KRW investment secured last September was moved up by two months.

As of 9:52 AM on the 7th, Pharmaresearch is trading at 207,000 KRW, up 2.99% (6,000 KRW) from the previous trading day. It hit a peak of 211,000 KRW early in the session and is currently undergoing a slight correction. This surpasses the previous all-time high of 238,500 KRW recorded on the 23rd of last month.

Pharmaresearch secured a 200 billion KRW investment from the European private equity firm CVC Capital last September. Through a third-party allotment of paid-in capital increase, 1,175,647 redeemable convertible preferred shares were issued to CVC Capital in exchange for 200 billion KRW. The original payment date for the capital increase was December 4th, but it was changed to October 8th through a board resolution. CVC Capital is one of the largest European private equity firms managing assets worth approximately 280 trillion KRW.

With the change in the payment date for the capital increase, Pharmaresearch has secured liquidity amounting to 400 billion KRW, including the existing 200 billion KRW. Pharmaresearch is expected to use this 'ammunition' for strategic mergers and acquisitions (M&A) and research and development (R&D). In particular, it is anticipated to open new avenues in the rapidly growing global beauty and medical device industries.